Forecast Period 
Market Size (Base Year) 
Market Size (Forecast Year)
CAGRGlobal MicroRNA (miRNA) Market, By Research Tool (Services, Products), Application (Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Diseases, Neurological Diseases and Other), End-Use (Biotechnology and Pharmaceutical Companies, academic and Government Research Institutes and Others) – Industry Trends and Forecast to 2030.
MicroRNA (miRNA) Market Analysis and Size
Emerging microRNA (miRNA) tools for disease-associated analytical applications, immense traction gained by miRNA target prediction and identification, and continued widespread adoption of the majority of miRNA tools have all contributed to market growth over the years. Furthermore, miRNAs are among the most important potential biopharmaceutical candidates entering the commercial space for the development of potential future medicines.
Data Bridge Market Research analyses that the microRNA (miRNA) market which was USD 1173.86 million in 2022, is expected to reach USD 4178.66 million by 2030, at a CAGR of 17.2% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
MicroRNA (miRNA) Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015 - 2020) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Research Tool (Services, Products), Application (Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Diseases, Neurological Diseases and Other), End-Use (Biotechnology and Pharmaceutical Companies, academic and Government Research Institutes and Others) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Merck KGaA (Germany), QIAGEN (Germany), Thermo Fisher Scientific Inc. (U.S.), Synlogic (U.S.), GeneCopoeia, Inc (U.S.), Horizon Discovery Ltd. (U.K.), New England Biolabs (U.S.), Quantabio (U.S.), NanoString (U.S.), BioGenex (U.S.), SeqMatic LLC (U.S.), Miltenyi Biotec (Germany), Agilent Technologies, Inc (U.S.), Promega Corporation (U.S.), Abcam plc (U.K.), KANEKA CORPORATION (Japan) |
|
Market Opportunities |
|
Market Definition
MicroRNAs (miRNAs) are endogenous small RNAs that regulate gene expression post-transcriptionally. MiRNA research in allergy is expanding because miRNAs are important regulators of gene expression and promising biomarker candidates. MiRNA mimics and inhibitors are currently in preclinical development as novel therapeutic agents.
Global MicroRNA (miRNA) Market Dynamics
Drivers
- Increasing use of microRNA
The increasing use of microRNA as a biomarker is also propelling the market. These biomarkers are significant in genome-wide population studies and data-driven methods because they have high robustness and reproducibility compared to traditional procedures. As a result, such molecules are promising drug candidate for the development of biomarkers. Furthermore, growing interest in liquid-based biopsies has increased its importance in biomarker discovery and development.
- Surge in research into the potential of miRNA biomarkers
A surge in research into the potential of miRNA biomarkers in prognosis, diagnosis, and therapeutics is expected to favour market expansion in the near future. For instance, in January 2020, researchers used next-generation sequencing to investigate the possibility of miRNA found in peripheral blood as a biomarker for diagnosing Bipolar II disorder (BD-II). MiRNAs could be a noninvasive solution for diagnosing other neurodegenerative diseases.
Opportunities
- Technological innovations
Technological innovation for improving the sensitivity and selectivity of miRNA detection contributes to the microRNA market's growth. Nanoparticle-based amplification, RCA-based, DSN-based, LAMP-based, and enzyme-free amplification are among the newly developed methods for miRNA detection. Similarly, researchers developed a program-based isothermal amplification technique for specific and quantitative digital measurement of miRNA in January 2020. The system can reduce contamination because it is based on signal amplification rather than direct replication of the targeted sequence, as is done with PCR-based approaches.
Restraints/Challenges
- High cost of MicroRNA kits
High cost of microRNA kits and other products will act as a restrain, and further hinder the growth of the microRNA (miRNA) market in the forecast period of 2023-2030.
This microRNA (miRNA) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the microRNA (miRNA) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In July 2020, Sistemic Ltd announced the expansion of its patent covering the use of microRNAs as predictive analytes for cellular function. The patent covers microRNA expression analysis of mesenchymal stem cells obtained from various donors to identify miRNAs that will be linked to cellular functions to support donor screening and the development of MSC-based cell therapies.
- In May 2020, DiamiR received U.S. Patent approval for miRNA-based methods for detecting and monitoring brain aging. The patent covers the use of methods for quantitative analysis of detectable miRNA in blood plasma and brain as brain ageing biomarkers.
Global MicroRNA (miRNA) Market Scope
The microRNA (miRNA) market is segmented on the basis of research tool, application and end-use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Research Tool
- Services
- Sample collection
- Whole blood
- Serum and plasma
- miRNA cDNA synthesis
- Profiling and purification
- Detection
- Functional studies
- NGS
- Microarray
- Real time
- Others
- Products
- Instruments
- Technology
- Real Time PCR
- Microarray
- NGS
- Others
- Workflow
- Isolation & Purification
- Whole Blood
- Serum
- Plasma
- FFPE
- Fresh Frozen Tissue
- Others
- Kits
- Reagents and consumables
- Isolation and purification
- Quantification and detection
- Functional analysis and others
Application
- Cancer
- Infectious Diseases
- Immunological Disorder
- Cardiovascular Diseases
- Neurological Diseases
- Other
End-Use
- Biotechnology
- Pharmaceutical Companies
- Academic
- Government Research Institutes
- Others
MicroRNA (miRNA) Market Regional Analysis/Insights
The microRNA (miRNA) market is analyzed and market size insights and trends are provided by country, research tool, application and end-use as referenced above.
The countries covered in the microRNA (miRNA) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the microRNA (miRNA) market due to the presence of strong technical support and well-established research infrastructure.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the rapid advancement in genomic studies and the adoption of new tools for supporting research endeavours.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The microRNA (miRNA) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for microRNA (miRNA) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the microRNA (miRNA) market. The data is available for historic period 2011-2021.
Competitive Landscape and MicroRNA (miRNA) Market Share Analysis
The microRNA (miRNA) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to microRNA (miRNA) market.
Some of the major players operating in the microRNA (miRNA) market are:
- Merck KGaA (Germany)
- QIAGEN (Germany)
- Thermo Fisher Scientific Inc. (U.S.)
- Synlogic (U.S.)
- GeneCopoeia, Inc (U.S.)
- Horizon Discovery Ltd. (U.K.)
- New England Biolabs (U.S.)
- Quantabio (U.S.)
- NanoString (U.S.)
- BioGenex (U.S.)
- SeqMatic LLC (U.S.)
- Miltenyi Biotec (Germany)
- Agilent Technologies, Inc (U.S.)
- Promega Corporation (U.S.)
- Abcam plc (U.K.)
- KANEKA CORPORATION (Japan)
SKU-
